Overview on Pathophysiology and Newer Approaches to Treatment of Peripheral Neuropathies

Authors: Vanotti, Alessandra; Osio, Maurizio; Mailland, Enrico; Nascimbene, Caterina; Capiluppi, Elisa; Mariani, Claudio

Source: CNS Drugs, Volume 21, Supplement 1, 2007 , pp. 3-12(10)

Publisher: Adis International

Buy & download fulltext article:

OR

Price: $57.95 plus tax (Refund Policy)

Abstract:

Peripheral neuropathies are extremely heterogeneous nosological entities. One of the most common symptoms is pain, the underlying mechanisms of which are numerous and complex. Inflammation, reparative processes, and anatomical and gene expression alterations lead to chronic pain, the persistence of which is sustained by peripheral and central sensitisation mechanisms. Treatment of peripheral neuropathies is targeted to its symptomatic and aetiological features. For pain relief, several types of drugs may be used, notably antidepressants (e.g. tricyclic antidepressants, selective serotonin reuptake inhibitors, and both serotonin and noradrenaline [norepinephrine] reuptake inhibitors), antiepileptic drugs (e.g. carbamazepine, phenytoin, lamotrigine, valproic acid, gabapentin, topiramate and pregabalin), NSAIDs and opioid analgesics. Aetiological therapy is aimed at modifying the pathophysiological mechanisms underlying the neuropathy, some of which are common in different neuropathic conditions. Certain drugs are known to exert more than one action on different pathophysiological mechanisms. This is the case with acetyl-L-carnitine (ALC), which can be considered both a symptomatic therapy that can be used in any kind of painful neuropathy, and an aetiological therapy, at least in diabetic neuropathy and neuropathies induced by nucleoside reverse transcriptase inhibitors and cancer chemotherapeutic agents. ALC acts via several mechanisms, inducing regeneration of injured nerve fibres, reducing oxidative stress, supporting DNA synthesis in mitochondria, and enhancing nerve growth factor concentrations in neurons.

Keywords: Antidepressants; Antiepileptic drugs; Antineoplastics; Cancer; Diabetic neuropathies; HIV infections; Levacecarnine; Nucleoside reverse transcriptase inhibitors; Opioid analgesics; Peripheral nerve disorders

Document Type: Review article

Affiliations: 1: U.O. Neurologia, Ospedale Luigi Sacco, Milan, Italy

Publication date: 2007-01-01

Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page